Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

Literature DB >> 29562193

Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.

Abstract

The success of immune checkpoint blockade in patients with a wide variety of malignancies has changed the treatment paradigm in oncology. However, combination therapies with immune checkpoint blockade will be needed to overcome resistance and broaden the clinical utility of immunotherapy. Here we discuss a framework for rationally designing combination therapy strategies based on enhancing major discriminatory functions of the immune system that are corrupted by cancer-namely, antigenicity, adjuvanticity, and homeostatic feedback inhibition. We review recent advances on how conventional genotoxic cancer therapies, molecularly targeted therapies, epigenetic agents, and immune checkpoint inhibitors can restore these discriminatory functions. Potential barriers that can impede response despite combination therapy are also discussed.

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2018 PMID： 29562193 PMCID： PMC6948191 DOI： 10.1016/j.immuni.2018.03.007

Source DB: PubMed Journal: Immunity ISSN： 1074-7613 Impact factor: 31.745

168 in total

1. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Authors: Juan Fu; David B Kanne; Meredith Leong; Laura Hix Glickman; Sarah M McWhirter; Edward Lemmens; Ken Mechette; Justin J Leong; Peter Lauer; Weiqun Liu; Kelsey E Sivick; Qi Zeng; Kevin C Soares; Lei Zheng; Daniel A Portnoy; Joshua J Woodward; Drew M Pardoll; Thomas W Dubensky; Young Kim
Journal: Sci Transl Med Date: 2015-04-15 Impact factor: 17.956

2. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors: Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal: Cancer Cell Date: 2017-02-13 Impact factor: 31.743

3. CD4⁺ T Cell Help Confers a Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased Tissue Invasiveness.

Authors: Tomasz Ahrends; Aldo Spanjaard; Bas Pilzecker; Nikolina Bąbała; Astrid Bovens; Yanling Xiao; Heinz Jacobs; Jannie Borst
Journal: Immunity Date: 2017-11-07 Impact factor: 31.745

4. Genetic basis for clinical response to CTLA-4 blockade in melanoma.

Authors: Alexandra Snyder; Vladimir Makarov; Taha Merghoub; Jianda Yuan; Jedd D Wolchok; Timothy A Chan; Jesse M Zaretsky; Alexis Desrichard; Logan A Walsh; Michael A Postow; Phillip Wong; Teresa S Ho; Travis J Hollmann; Cameron Bruggeman; Kasthuri Kannan; Yanyun Li; Ceyhan Elipenahli; Cailian Liu; Christopher T Harbison; Lisu Wang; Antoni Ribas
Journal: N Engl J Med Date: 2014-11-19 Impact factor: 91.245

5. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy.

Authors: Stefani Spranger; Daisy Dai; Brendan Horton; Thomas F Gajewski
Journal: Cancer Cell Date: 2017-05-08 Impact factor: 31.743

6. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Authors: Leticia Corrales; Laura Hix Glickman; Sarah M McWhirter; David B Kanne; Kelsey E Sivick; George E Katibah; Seng-Ryong Woo; Edward Lemmens; Tamara Banda; Justin J Leong; Ken Metchette; Thomas W Dubensky; Thomas F Gajewski
Journal: Cell Rep Date: 2015-05-07 Impact factor: 9.423

7. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors: Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal: N Engl J Med Date: 2017-09-08 Impact factor: 91.245

8. Toll-like receptor 3 ligand polyinosinic:polycytidylic acid promotes wound healing in human and murine skin.

Authors: Qing Lin; Li Wang; Youkun Lin; Xialin Liu; Xiangrong Ren; Sijian Wen; Xiaolin Du; Tao Lu; Sarah Y Su; Xiaoping Yang; Wenlin Huang; Shiyou Zhou; Feng Wen; Shao Bo Su
Journal: J Invest Dermatol Date: 2012-05-10 Impact factor: 8.551

9. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

Authors: Sanjeev Mariathasan; Shannon J Turley; Dorothee Nickles; Alessandra Castiglioni; Kobe Yuen; Yulei Wang; Edward E Kadel; Hartmut Koeppen; Jillian L Astarita; Rafael Cubas; Suchit Jhunjhunwala; Romain Banchereau; Yagai Yang; Yinghui Guan; Cecile Chalouni; James Ziai; Yasin Şenbabaoğlu; Stephen Santoro; Daniel Sheinson; Jeffrey Hung; Jennifer M Giltnane; Andrew A Pierce; Kathryn Mesh; Steve Lianoglou; Johannes Riegler; Richard A D Carano; Pontus Eriksson; Mattias Höglund; Loan Somarriba; Daniel L Halligan; Michiel S van der Heijden; Yohann Loriot; Jonathan E Rosenberg; Lawrence Fong; Ira Mellman; Daniel S Chen; Marjorie Green; Christina Derleth; Gregg D Fine; Priti S Hegde; Richard Bourgon; Thomas Powles
Journal: Nature Date: 2018-02-14 Impact factor: 49.962

10. Cancer therapies activate RIG-I-like receptor pathway through endogenous non-coding RNAs.

Authors: Diana Rose E Ranoa; Akash D Parekh; Sean P Pitroda; Xiaona Huang; Thomas Darga; Anthony C Wong; Lei Huang; Jorge Andrade; Jonathan P Staley; Takashi Satoh; Shizuo Akira; Ralph R Weichselbaum; Nikolai N Khodarev
Journal: Oncotarget Date: 2016-05-03

155 in total

Review 1. Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.

Authors: Yasunori Minami; Naoshi Nishida; Masatoshi Kudo
Journal: Eur Radiol Date: 2019-04-08 Impact factor: 5.315

2. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.

Authors: Xiaoguang Wang; Brittany C Waschke; Rachel A Woolaver; Zhangguo Chen; Gan Zhang; Anthony D Piscopio; Xuedong Liu; Jing H Wang
Journal: Cancer Immunol Res Date: 2019-06-24 Impact factor: 11.151

3. The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory.

Authors: Jeffrey West; Mark Robertson-Tessi; Kimberly Luddy; Derek S Park; Drew F K Williamson; Cathal Harmon; Hung T Khong; Joel Brown; Alexander R A Anderson
Journal: JCO Clin Cancer Inform Date: 2019-02

4. Human Papillomavirus E7 Oncoprotein Subverts Host Innate Immunity via SUV39H1-Mediated Epigenetic Silencing of Immune Sensor Genes.

Authors: Irene Lo Cigno; Federica Calati; Cinzia Borgogna; Alessandra Zevini; Silvia Albertini; Licia Martuscelli; Marco De Andrea; John Hiscott; Santo Landolfo; Marisa Gariglio
Journal: J Virol Date: 2020-01-31 Impact factor: 5.103

5. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy.

Authors: Qiang Zhang; Michael D Green; Weiping Zou; Meredith A Morgan; Xueting Lang; Jenny Lazarus; Joshua D Parsels; Shuang Wei; Leslie A Parsels; Jiaqi Shi; Nithya Ramnath; Daniel R Wahl; Marina Pasca di Magliano; Timothy L Frankel; Ilona Kryczek; Yu L Lei; Theodore S Lawrence
Journal: Cancer Res Date: 2019-05-17 Impact factor: 12.701

9. Combination immune checkpoint inhibitors with platinum-based chemotherapy in advanced non-small cell lung cancer: what's known and what's next.

Authors: Tao Jiang; Caicun Zhou; Jie Hu; Yuanlin Song
Journal: Transl Lung Cancer Res Date: 2019-12

10. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.

Authors: Stephen J Bagley; Wei-Ting Hwang; Steven Brem; Gerald P Linette; Donald M O'Rourke; Arati S Desai
Journal: J Neurooncol Date: 2018-10-23 Impact factor: 4.130